PDUFA Date
OTLK: FDA Decision: lytenava
July 24, 2026 · lytenava · approval. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 24, 2026
- Company
- Outlook Therapeutics, Inc. (OTLK)
- Drug
- lytenava
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
PDUFA Dateapproval
FDA Decision: lytenava
- Drug
- lytenava
- Indication
- 1 INDICATIONS AND USAGE LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD). LYTENAVA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) ( 1 ).